Europe Human Papillomavirus (HPV) Vaccine Market Forecast to 2028

Report Code : BMIRE00026300 | Region : Europe | Industry : Pharmaceuticals | Published Date : 26/Sep/2022
Europe Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)

The Europe human papillomavirus (HPV) vaccine market is expected to grow from US$ 1,202.66 million in 2022 to US$ 1,598.81 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2022 to 2028.

Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is driving the market. In women, cervical cancer is the fourth most common cancer. In addition, as per the report, titled “Human Papillomavirus and Related Diseases Report-Europe,” in 2020, 8,449 women and 4,327 men had anal cancer in Europe. Such a high incidence rate of HPV-associated infections is favoring the market growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe human papillomavirus (HPV) vaccine market . The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

Europe Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Europe Human Papillomavirus (HPV) Vaccine Market Segmentation

The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022. Based on dosage, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022. Based on age, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022. Based on application, the Europe human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022. Based on end user, the Europe human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022. Based on country, the Europe human papillomavirus (HPV) vaccine market has been categorized into the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe. Germany would dominate the market in 2022.

2A Pharma ; ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.

The List of Companies - Europe Human Papillomavirus (HPV) Vaccine Market

● 2A Pharma

● ChengDu Institute of Biological Products Co., Ltd.

● GlaxoSmithKline plc.

● Inovio Pharmaceuticals

● Merck & Co., Inc. 

● R-Pharm

● Sanofi

● Serum Institute of India Pvt. Ltd

● Vaccitech  

● Walvax Biotechnology Co., Ltd.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Human Papillomavirus (HPV) Vaccines Market – By Type

1.3.2 Europe Human Papillomavirus (HPV) Vaccines Market – By Dosage

1.3.3 Europe Human Papillomavirus (HPV) Vaccines Market – By Age

1.3.4 Europe Human Papillomavirus (HPV) Vaccines Market – By Application

1.3.5 Europe Human Papillomavirus (HPV) Vaccines Market – By Distribution Channel

1.3.6 Europe Human Papillomavirus (HPV) Vaccines Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Human Papillomavirus (HPV) Vaccine Market – Market Landscape

4.1 Overview

4.2 Europe PEST Analysis

4.3 Experts Opinion

5. Europe Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increase in Prevalence of HPV Associated Diseases

5.1.2 Initiatives Taken by Health Organizations

5.2 Market Restraints

5.2.1 High Cost of HPV Vaccines

5.3 Market Opportunities

5.3.1 Growing Number of HPV Awareness Programs

5.4 Future Trends

5.4.1 Advancements in HPV Diagnostics Tests

5.5 Impact Analysis

6. Human Papillomavirus (HPV) Vaccine Market– Europe Analysis

6.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis

7. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – By Type

7.1 Overview

7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)

7.3 9-valent HPV vaccine

7.3.1 Overview

7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.4 Quadrivalent HPV vaccine

7.4.1 Overview

7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.5 Bivalent HPV Vaccine

7.5.1 Overview

7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)

8. Europe Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage

8.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)

8.2 2 Dose

8.2.1 Overview

8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

8.3 3 Dose

8.3.1 Overview

8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Human Papillomavirus (HPV) Vaccine Market Analysis - By Age

9.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)

9.2 9 to 14 Years

9.2.1 Overview

9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9.3 to 45 Years

9.3.1 Overview

9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Human Papillomavirus (HPV) Vaccine Market Analysis - By Application

10.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)

10.2 HPV-attributable Cancer

10.2.1 Overview

10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10.3 Genital Warts

10.3.1 Overview

10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – By End User

11.1 Overview

11.2 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)

11.3 Doctor Office

11.3.1 Overview

11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)

11.4 Community Health Clinics

11.4.1 Overview

11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)

11.5 School-based Health Centers

11.5.1 Overview

11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)

11.6 Health Departments

11.6.1 Overview

11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)

11.7 Hospitals

11.7.1 Overview

11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)

11.8 Others

11.8.1 Overview

11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)

12. Europe Human Papillomavirus (HPV) Vaccine Market - Country Analysis

12.1 Overview

12.1.1 Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

12.1.1.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.2 Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.3 Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.4 Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.5 Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.6 Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.1 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.2 France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.3 France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.4 France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.5 France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.6 France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.1 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.2 UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.3 UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.4 UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.5 UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.6 UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.1 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.2 Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.3 Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.4 Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.5 Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.6 Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.1 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.2 Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.3 Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.4 Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.5 Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.6 Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.1 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.2 Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.3 Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.4 Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.5 Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.6 Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.1 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.2 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.3 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.4 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.5 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.6 Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.1 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.2 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.3 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.4 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.5 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.6 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

13. Industry Landscape

13.1 Overview

13.2 Inorganic Growth Strategies

13.2.1 Overview

13.3 Organic Growth Strategies

13.3.1 Overview

14. Company Profiles

14.1 Merck & Co., Inc.

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 GlaxoSmithKline plc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Serum Institute of India Pvt. Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 Walvax Biotechnology Co., Ltd.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Inovio Pharmaceuticals

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Vaccitech

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 2A Pharma

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 ChengDu Institute of Biological Products Co., Ltd.

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Sanofi

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

14.10 R-Pharm

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Products and Services

14.10.4 Financial Overview

14.10.5 SWOT Analysis

14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1.             Europe Human Papillomavirus (HPV) Vaccine Market, Revenue and Forecast, 2019–2028 (US$ Mn)

Table 2.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 4.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 5.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7.             France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 8.             France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 9.             France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 10.          France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 11.          France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 12.          UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 13.          UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 14.          UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 15.          UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 16.          UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 19.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 20.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 23.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 24.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 25.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 26.          Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 27.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 28.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 29.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 30.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 31.          Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 32.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 33.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 34.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 35.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 36.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 37.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 38.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 39.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 40.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 41.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 42.          Recent Inorganic Growth Strategies

Table 43.          Recent Organic Growth Strategies

Table 44.          Glossary of Terms

The List of Companies - Europe Human Papillomavirus (HPV) Vaccine Market

● 2A Pharma

● ChengDu Institute of Biological Products Co., Ltd.

● GlaxoSmithKline plc.

● Inovio Pharmaceuticals

● Merck & Co., Inc. 

● R-Pharm

● Sanofi

● Serum Institute of India Pvt. Ltd

● Vaccitech  

● Walvax Biotechnology Co., Ltd.

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe human papillomavirus (HPV) vaccine market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Europe human papillomavirus (HPV) vaccine market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the human papillomavirus (HPV) vaccine market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Europe Human Papillomavirus (HPV) Vaccine Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry